Search results
Results From The WOW.Com Content Network
WuXi ATU’s new 140,000 sq. ft. state of the art laboratory will alleviate these challenges by significantly increasing analytical development and testing capacity and capability and enabling global advanced therapy companies to obtain timely characterization and lot release services.
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard.
February 20, 2024 – WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License ...
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma. AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA, PA.
PHILADELPHIA, Nov. 15, 2021 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility...
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard.
WuXi Advanced Therapies is home to more than 900 employees and four state-of-the art manufacturing facilities and laboratories all located in a single campus at the Navy Yard in Philadelphia, PA. Watch this video for a four-minute tour and contact us to discuss your development, testing and manufacturing needs and schedule time to tour the site ...
NextUp: WuXi AppTec Is Speeding Up Drug Development Worldwide. The Chinese pharma company, with its deep South Philadelphia Navy Yard presence, is globally recognized for building an innovative...
4751 League Island Blvd . Philadelphia, PA 19112. WuXi Advanced Therapies locations are in Philadelphia, PA on the campus of the Navy Yard and feature more than 400,000 sq.ft. of space.
According to a company press release, the treatment is a tumor-derived autologous T cell immunotherapy, specifically developed for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody.